In vivo reflectance confocal microscopy can detect the invasive component of lentigo maligna melanoma: Prospective analysis and case-control study.


Journal

Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037

Informations de publication

Date de publication:
Jul 2023
Historique:
received: 24 09 2022
accepted: 08 02 2023
medline: 14 6 2023
pubmed: 2 3 2023
entrez: 1 3 2023
Statut: ppublish

Résumé

Lentigo maligna (LM), a form of melanoma in situ, has no risk of causing metastasis unless dermal invasive melanoma (LMM) supervenes. Furthermore, the detection of invasion impacts prognosis and management. To assess the accuracy of RCM for the detection of invasion component on LM/LMM lesions. In the initial case-control study, the performance of one expert in detecting LMM at the time of initial RCM assessment of LM/LMM lesions was recorded prospectively (n = 229). The cases were assessed on RCM-histopathology correlation sessions and a panel with nine RCM features was proposed to identify LMM, which was subsequently tested in a subset of initial cohort (n = 93) in the matched case-control study by two blinded observers. Univariable and multivariable logistic regression models were performed to evaluate RCM features predictive of LMM. Reproducibility of assessment of the nine RCM features was also evaluated. A total of 229 LM/LMM cases evaluated by histopathology were assessed blindly and prospectively by an expert confocalist. On histopathology, 210 were LM and 19 were LMM cases. Correct identification of an invasive component was achieved for 17 of 19 LMM cases (89%) and the absence of a dermal component was correctly diagnosed in 190 of 210 LM cases (90%). In the matched case-control (LMM n = 35, LM n = 58), epidermal and junctional disarray, large size of melanocytes and nests of melanocytes were independent predictors of LMM on multivariate analysis. The interobserver analysis demonstrated that these three features had a fair reproducibility between the two investigators (K = 0.4). The multivariable model including those three features showed a high predictive performance AUC = 74% (CI 95% 64-85%), with sensitivity of 63% (95% CI 52-78%) and specificity of 79% (CI 95% 74-88%), and likelihood ratio of 18 (p-value 0.0026). Three RCM features were predictive for identifying invasive melanoma in the background of LM.

Sections du résumé

BACKGROUND BACKGROUND
Lentigo maligna (LM), a form of melanoma in situ, has no risk of causing metastasis unless dermal invasive melanoma (LMM) supervenes. Furthermore, the detection of invasion impacts prognosis and management.
OBJECTIVE OBJECTIVE
To assess the accuracy of RCM for the detection of invasion component on LM/LMM lesions.
METHODS METHODS
In the initial case-control study, the performance of one expert in detecting LMM at the time of initial RCM assessment of LM/LMM lesions was recorded prospectively (n = 229). The cases were assessed on RCM-histopathology correlation sessions and a panel with nine RCM features was proposed to identify LMM, which was subsequently tested in a subset of initial cohort (n = 93) in the matched case-control study by two blinded observers. Univariable and multivariable logistic regression models were performed to evaluate RCM features predictive of LMM. Reproducibility of assessment of the nine RCM features was also evaluated.
RESULTS RESULTS
A total of 229 LM/LMM cases evaluated by histopathology were assessed blindly and prospectively by an expert confocalist. On histopathology, 210 were LM and 19 were LMM cases. Correct identification of an invasive component was achieved for 17 of 19 LMM cases (89%) and the absence of a dermal component was correctly diagnosed in 190 of 210 LM cases (90%). In the matched case-control (LMM n = 35, LM n = 58), epidermal and junctional disarray, large size of melanocytes and nests of melanocytes were independent predictors of LMM on multivariate analysis. The interobserver analysis demonstrated that these three features had a fair reproducibility between the two investigators (K = 0.4). The multivariable model including those three features showed a high predictive performance AUC = 74% (CI 95% 64-85%), with sensitivity of 63% (95% CI 52-78%) and specificity of 79% (CI 95% 74-88%), and likelihood ratio of 18 (p-value 0.0026).
CONCLUSION CONCLUSIONS
Three RCM features were predictive for identifying invasive melanoma in the background of LM.

Identifiants

pubmed: 36855833
doi: 10.1111/jdv.18998
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1293-1301

Subventions

Organisme : Melanoma Institute Australia
Organisme : MetaOptima Technology Incl., Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, GlaxoSmithKline.
ID : N/A
Organisme : NHMRC Practitioner Fellowship
ID : APP1141295

Informations de copyright

© 2023 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

Références

Dermatol Surg. 2021 Apr 1;47(4):473-479
pubmed: 33625139
J Am Acad Dermatol. 2013 Mar;68(3):e73-82
pubmed: 22000768
Australas J Dermatol. 2019 May;60(2):118-125
pubmed: 30302753
J Invest Dermatol. 2010 Aug;130(8):2080-91
pubmed: 20393481
Int J Dermatol. 2022 Feb;61(2):167-174
pubmed: 34351639
J Eur Acad Dermatol Venereol. 2020 Jan;34(1):74-81
pubmed: 31325402
Melanoma Res. 2020 Apr;30(2):193-197
pubmed: 31095041
Dermatol Pract Concept. 2021 May 20;11(3):e2021068
pubmed: 34123564
Dermatol Clin. 2016 Oct;34(4):421-429
pubmed: 27692448
J Eur Acad Dermatol Venereol. 2023 Jul;37(7):1293-1301
pubmed: 36855833
J Clin Oncol. 2009 Dec 20;27(36):6199-206
pubmed: 19917835
Br J Dermatol. 2009 Dec;161(6):1307-16
pubmed: 19566662
J Am Acad Dermatol. 2023 Sep;89(3):e125-e126
pubmed: 35085680
Arch Dermatol Res. 2021 Sep;313(7):517-529
pubmed: 32844312
Dermatol Surg. 2018 Feb;44(2):159-174
pubmed: 29059147
J Eur Acad Dermatol Venereol. 2014 Aug;28(8):1069-78
pubmed: 24147614
Hum Pathol. 2000 Jun;31(6):705-8
pubmed: 10872664

Auteurs

Bruna Melhoranse Gouveia (BM)

Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.

Giuliana Carlos (G)

Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

Andreanne Wadell (A)

Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
CHUS - Hôtel-Dieu, Sherbrooke, Québec, Canada.

Christoph Sinz (C)

Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Department of Dermatology, Medical University of Vienna, Vienna, Austria.

Tasnia Ahmed (T)

Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.

Serigne N Lo (SN)

Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.

Robert V Rawson (RV)

Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia.

Peter M Ferguson (PM)

Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia.

Richard A Scolyer (RA)

Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and NSW Health Pathology, Sydney, New South Wales, Australia.
Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.

Pascale Guitera (P)

Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Sydney Melanoma Diagnostic Centre, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH